Literature DB >> 29353381

Effect of Kaempferol Pretreatment on Myocardial Injury in Rats.

Anamika Vishwakarma1, Thakur Uttam Singh2, Soya Rungsung1, Tarun Kumar1, Arunvikram Kandasamy1, Subhashree Parida1, Madhu Cholenahalli Lingaraju1, Ajay Kumar3, Asok Kumar4, Dinesh Kumar1.   

Abstract

The present study was undertaken to evaluate the effect of kaempferol in isoprenaline (ISP)-induced myocardial injury in rats. ISP was administered subcutaneously for two subsequent days to induce myocardial injury. Assessment of myocardial injury was done by estimation of hemodynamic functions, myocardial infarcted area, cardiac injury markers, lipid profile, oxidative stress, pro-inflammatory cytokines and histopathology of heart and liver. Rats pretreated with kaempferol showed reduction in the myocardial infarcted area and heart rate. However, no improvement was observed in change in body weight, mean arterial, systolic and diastolic blood pressure. Kaempferol showed significant decrease in serum LDH, CK-MB, troponin-I and lipid profile. However, highest dose of kaempferol did not reduce the serum triglyceride level. Further, antioxidant enzymes, SOD and catalase, were also higher. However, reduced glutathione, serum SGOT and creatinine did not show any improvement. Kaempferol showed reduction in MDA level. Kaempferol at highest dose showed reduction in pro-MMP-2 expression and MMP-9 level. mRNA expression level of TNF-α was not different in kaempferol-pretreated myocardial injured rats with ISP-alone group. Pretreatment with kaempferol at highest dose showed mild mononuclear infiltration and degenerative changes in heart tissue section of myocardial injured rats. Rats pretreated with kaempferol at higher concentration showed normal cordlike arrangement of hepatocytes with moderate swelling of hepatocytes (vacuolar degeneration) around the central vein. Study suggests that kaempferol attenuated lipid profile, infarcted area and oxidative stress in ISP-induced myocardial injury in rats.

Entities:  

Keywords:  Isoprenaline; Kaempferol; Myocardial injury; Rats

Mesh:

Substances:

Year:  2018        PMID: 29353381     DOI: 10.1007/s12012-018-9443-5

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  6 in total

1.  The Protective Effects of Compound 21 and Valsartan in Isoproterenol-Induced Myocardial Injury in Rats.

Authors:  Zeynep Ulutas; Necip Ermis; Onural Ozhan; Hakan Parlakpinar; Nigar Vardi; Burhan Ates; Cemil Colak
Journal:  Cardiovasc Toxicol       Date:  2020-07-09       Impact factor: 3.231

2.  Analysis of the mechanism of Shufeng Jiedu capsule prevention and treatment for COVID-19 by network pharmacology tools.

Authors:  Haijun Xiong; Zhaowei Dong; Guanhua Lou; Qingxia Gan; Jin Wang; Qinwan Huang
Journal:  Eur J Integr Med       Date:  2020-10-30       Impact factor: 1.314

3.  Insights into the molecular mechanisms of Huangqi decoction on liver fibrosis via computational systems pharmacology approaches.

Authors:  Biting Wang; Zengrui Wu; Weihua Li; Guixia Liu; Yun Tang
Journal:  Chin Med       Date:  2021-07-23       Impact factor: 5.455

4.  Protective Effect of Kaempferol and Its Nanoparticles on 5-Fluorouracil-Induced Cardiotoxicity in Rats.

Authors:  Soheila Safarpour; Marzieh Pirzadeh; Anahita Ebrahimpour; Fatemeh Shirafkan; Fateme Madani; Mohammad Hosseini; Ali Akbar Moghadamnia; Sohrab Kazemi
Journal:  Biomed Res Int       Date:  2022-02-13       Impact factor: 3.411

5.  Recent studies on kaempferol and its biological and pharmacological activities.

Authors:  Jae Kwang Kim; Sang Un Park
Journal:  EXCLI J       Date:  2020-05-13       Impact factor: 4.068

6.  The Protective Effect of Kaempferol Against Ischemia/Reperfusion Injury Through Activating SIRT3 to Inhibit Oxidative Stress.

Authors:  Chuang Sun; Tingting Wang; Changying Wang; Zhenyin Zhu; Xiaoni Wang; Jia Xu; Huixian An
Journal:  Braz J Cardiovasc Surg       Date:  2022-05-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.